On April 21, 2023 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that it will present data from two studies highlighting the performance of its blood-based screening technology to detect early-stage colorectal cancer (CRC), including the acceptance of the ECLIPSE study as a late-breaking abstract, at Digestive Disease Week (DDW) taking place in Chicago, Illinois on May 6-9, 2023 (Press release, Guardant Health, APR 21, 2023, https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-announces-new-data-to-be-presented-at-2023-Digestive-Disease-Week-showcasing-the-potential-of-its-blood-based-technology-to-detect-colorectal-cancer/default.aspx [SID1234630383]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Despite multiple screening modalities for colorectal cancer, screening rates remain stubbornly low leaving many cancers undetected. A blood test that can accurately detect CRC represents a significant opportunity to overcome some of the known challenges with patient adherence," said AmirAli Talasaz, Guardant Health co-CEO. "We are thrilled that DDW has accepted the ECLIPSE study, one of the largest studies of its kind, as a late-breaking abstract, and we look forward to sharing this new data with the healthcare community at this year’s meeting."
"The need for a convenient, less invasive way to screen for CRC is great, and an accurate blood test can play a critical role in improving screening rates, especially for those reluctant to get screened," said Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. "I look forward to presenting at DDW and sharing new data from the ECLIPSE Study on the performance and potential of the Shield blood test to help improve adherence to screening."
The ECLIPSE Study late-breaking abstract and one additional abstract highlighting the potential of Guardant Health’s blood-based screening technology are now available online through the DDW meeting planner. The presentation on Tuesday, May 9 will include further data and trial design analysis beyond what is included in the online abstract. Details of the presentations are as follows:
Abstract
Session
Title
Tuesday, May 9 | 9:00-9:15am CT
#3910067
DDW Clinical Late Breaking Session #5095
Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population
Presenter: Daniel Chung, MD, gastroenterologist at Massachusetts General Hospital and professor of medicine at Harvard Medical School
Tuesday, May 9 | 12:30-1:30pm CT
#Tu1132
Poster Session #9050
Assessment of an Early Version Blood Based Multimodal cfDNA Assay for the Detection of Colorectal Cancer Incorporating the Assessment of ctDNA Genomic Alterations and Epigenomic Modifications